Document is current
Any future updates will be listed below
-
Authors
Meems, Laura M. G. https://orcid.org/0000-0001-8627-7139
van Veldhuisen, Dirk J.
Sattar, Naveed https://orcid.org/0000-0002-1604-2593
Lee, Matthew M. Y. https://orcid.org/0000-0001-9213-2067
- License Information
-
More Information
Article History
Accepted: 3 July 2025
First Online: 28 July 2025
Competing interests
: L.M.G.M. reports consulting/speaker honoraria received through her institution from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novartis, Novo Nordisk and Pfizer, and is a member of a trial steering committee for Relaxera. N.S. reports consulting/speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Menarini-Ricerche, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics and Sanofi, and grants from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. M.M.Y.L. has received research grants through his institution (the University of Glasgow) from AstraZeneca, Boehringer Ingelheim and Roche Diagnostics, and is a member of trial steering committees for Amgen and Cytokinetics and clinical end point committees for Bayer and GlaxoSmithKline. D.J.v.V. declares no competing interests.
